MedTrace Logo

Comparison of Anyu Peibo With Placebo in Treatment of MDD in China

NCT04210973 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2020-05-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression.

Conditions

Interventions

DRUG

Anyu Peibo

Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper

DRUG

Placebo

Placebo Capsule, twice per day, oral after breakfast and supper

Sponsors & Collaborators

  • Su Zhou YiHua Biotechnology Co. LTD

    collaborator UNKNOWN

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Huafang LI, MD. PhD. · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-23
Primary Completion
2020-12-31
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04210973 on ClinicalTrials.gov